Browse BTK

Summary
SymbolBTK
NameBruton agammaglobulinemia tyrosine kinase
Aliases ATK; XLA; PSCTK1; AGMX1; IMD1; BPK; B-cell progenitor kinase; agammaglobulinaemia tyrosine kinase; dominant- ......
Chromosomal LocationXq21.33-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Cell membrane; Peripheral membrane protein. Nucleus. Note=In steady state, BTK is predominantly cytosolic. Following B-cell receptor (BCR) engagement by antigen, translocates to the plasma membrane through its PH domain. Plasma membrane localization is a critical step in the activation of BTK. A fraction of BTK also shuttles between the nucleus and the cytoplasm, and nuclear export is mediated by the nuclear export receptor CRM1.
Domain PF00779 BTK motif
PF00169 PH domain
PF07714 Protein tyrosine kinase
PF00017 SH2 domain
PF00018 SH3 domain
Function

Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members. PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK. BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways. Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway. The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense. Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells. Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation. BTK plays also a critical role in transcription regulation. Induces the activity of NF-kappa-B, which is involved in regulating the expression of hundreds of genes. BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B. Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR. GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression. ARID3A and NFAT are other transcriptional target of BTK. BTK is required for the formation of functional ARID3A DNA-binding complexes. There is however no evidence that BTK itself binds directly to DNA. BTK has a dual role in the regulation of apoptosis.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001783 B cell apoptotic process
GO:0001802 type III hypersensitivity
GO:0001803 regulation of type III hypersensitivity
GO:0001805 positive regulation of type III hypersensitivity
GO:0001810 regulation of type I hypersensitivity
GO:0001812 positive regulation of type I hypersensitivity
GO:0001818 negative regulation of cytokine production
GO:0001821 histamine secretion
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002238 response to molecule of fungal origin
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002279 mast cell activation involved in immune response
GO:0002349 histamine production involved in inflammatory response
GO:0002366 leukocyte activation involved in immune response
GO:0002367 cytokine production involved in immune response
GO:0002368 B cell cytokine production
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002437 inflammatory response to antigenic stimulus
GO:0002438 acute inflammatory response to antigenic stimulus
GO:0002440 production of molecular mediator of immune response
GO:0002441 histamine secretion involved in inflammatory response
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002448 mast cell mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002524 hypersensitivity
GO:0002526 acute inflammatory response
GO:0002532 production of molecular mediator involved in inflammatory response
GO:0002553 histamine secretion by mast cell
GO:0002673 regulation of acute inflammatory response
GO:0002675 positive regulation of acute inflammatory response
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002714 positive regulation of B cell mediated immunity
GO:0002718 regulation of cytokine production involved in immune response
GO:0002721 regulation of B cell cytokine production
GO:0002755 MyD88-dependent toll-like receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002861 regulation of inflammatory response to antigenic stimulus
GO:0002863 positive regulation of inflammatory response to antigenic stimulus
GO:0002864 regulation of acute inflammatory response to antigenic stimulus
GO:0002866 positive regulation of acute inflammatory response to antigenic stimulus
GO:0002883 regulation of hypersensitivity
GO:0002885 positive regulation of hypersensitivity
GO:0002886 regulation of myeloid leukocyte mediated immunity
GO:0002888 positive regulation of myeloid leukocyte mediated immunity
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002891 positive regulation of immunoglobulin mediated immune response
GO:0002902 regulation of B cell apoptotic process
GO:0006887 exocytosis
GO:0006979 response to oxidative stress
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007498 mesoderm development
GO:0009620 response to fungus
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0016064 immunoglobulin mediated immune response
GO:0016068 type I hypersensitivity
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019722 calcium-mediated signaling
GO:0019724 B cell mediated immunity
GO:0019932 second-messenger-mediated signaling
GO:0021700 developmental maturation
GO:0023061 signal release
GO:0030098 lymphocyte differentiation
GO:0030183 B cell differentiation
GO:0031349 positive regulation of defense response
GO:0032103 positive regulation of response to external stimulus
GO:0032418 lysosome localization
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0038083 peptidyl-tyrosine autophosphorylation
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0042113 B cell activation
GO:0043299 leukocyte degranulation
GO:0043303 mast cell degranulation
GO:0045055 regulated exocytosis
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045117 azole transport
GO:0045576 mast cell activation
GO:0045577 regulation of B cell differentiation
GO:0045579 positive regulation of B cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0046777 protein autophosphorylation
GO:0046879 hormone secretion
GO:0048469 cell maturation
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050853 B cell receptor signaling pathway
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050871 positive regulation of B cell activation
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051608 histamine transport
GO:0051640 organelle localization
GO:0051656 establishment of organelle localization
GO:0070227 lymphocyte apoptotic process
GO:0070228 regulation of lymphocyte apoptotic process
GO:0071216 cellular response to biotic stimulus
GO:0071226 cellular response to molecule of fungal origin
GO:0071887 leukocyte apoptotic process
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:2000106 regulation of leukocyte apoptotic process
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004715 non-membrane spanning protein tyrosine kinase activity
GO:0005543 phospholipid binding
GO:0005547 phosphatidylinositol-3,4,5-trisphosphate binding
GO:0035091 phosphatidylinositol binding
GO:1901981 phosphatidylinositol phosphate binding
Cellular Component GO:0009898 cytoplasmic side of plasma membrane
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0031234 extrinsic component of cytoplasmic side of plasma membrane
GO:0042629 mast cell granule
GO:0045121 membrane raft
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04064 NF-kappa B signaling pathway
hsa04380 Osteoclast differentiation
hsa04611 Platelet activation
hsa04662 B cell receptor signaling pathway
hsa04664 Fc epsilon RI signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-1280218: Adaptive Immune System
R-HSA-983695: Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1643685: Disease
R-HSA-5602358: Diseases associated with the TLR signaling cascade
R-HSA-5260271: Diseases of Immune System
R-HSA-1236974: ER-Phagosome pathway
R-HSA-2871809: FCERI mediated Ca+2 mobilization
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-5603041: IRAK4 deficiency (TLR2/4)
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-5602498: MyD88 deficiency (TLR2/4)
R-HSA-166058: MyD88
R-HSA-195258: RHO GTPase Effectors
R-HSA-5663213: RHO GTPases Activate WASPs and WAVEs
R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
Summary
SymbolBTK
NameBruton agammaglobulinemia tyrosine kinase
Aliases ATK; XLA; PSCTK1; AGMX1; IMD1; BPK; B-cell progenitor kinase; agammaglobulinaemia tyrosine kinase; dominant- ......
Chromosomal LocationXq21.33-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BTK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BTK and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26715645Pancreatic CarcinomaInhibit immunityHere, we report that targeting Bruton tyrosine kinase (BTK), a key B-cell and macrophage kinase, restores T cell-dependent antitumor immune responses, thereby inhibiting PDAC growth and improving responsiveness to standard-of-care chemotherapy.
26880800Melanoma; Breast CarcinomaInhibit immunity (T cell function)Ibrutinib treatment also resulted in a significant reduction of MDSCs in wild-type mice bearing B16F10 melanoma tumors, but not in X-linked immunodeficiency mice (XID) harboring a BTK mutation, suggesting that BTK inhibition plays an important role in the observed reduction of MDSCs in vivo
27479178Chronic Lymphocytic LeukemiaPromote immunityFurthermore, we report that CLL monocytes express Bruton's tyrosine kinase (BTK). Our observations suggest that using BTK inhibitors in CLL might further aggravate the observed immune metabolic defects in monocytes. Triggering the programmed cell death-1 (PD-1) checkpoint on monocytes hampers glycolysis, phagocytosis and BTK signaling. Conversely, disrupting PD-1/PD-L1 signaling reverses these immune metabolic dysfunctions. Taken together, our findings imply a novel metabolic interplay between CLL cells and monocytes and that blocking PD-1/PD-L1 might restore metabolic together with antitumor activity of CLL monocytes/macrophages.
28714866Chronic Lymphocytic LeukemiaInhibit immunityPeripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) were collected serially. Both agents reduced expression of the immunosuppressive molecules CD200 and BTLA as well as IL-10 production by CLL cells. PD-1 and CTLA-4 expression was significantly markedly reduced in T cells by both agents.
Summary
SymbolBTK
NameBruton agammaglobulinemia tyrosine kinase
Aliases ATK; XLA; PSCTK1; AGMX1; IMD1; BPK; B-cell progenitor kinase; agammaglobulinaemia tyrosine kinase; dominant- ......
Chromosomal LocationXq21.33-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BTK in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBTK
NameBruton agammaglobulinemia tyrosine kinase
Aliases ATK; XLA; PSCTK1; AGMX1; IMD1; BPK; B-cell progenitor kinase; agammaglobulinaemia tyrosine kinase; dominant- ......
Chromosomal LocationXq21.33-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BTK in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2180.61
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.640.557
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0990.917
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0920.861
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5880.633
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9610.582
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2310.608
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5680.649
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1330.923
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8160.499
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.810.666
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2130.262
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BTK in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.76.8-3.11
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.78.5-4.80.66
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBTK
NameBruton agammaglobulinemia tyrosine kinase
Aliases ATK; XLA; PSCTK1; AGMX1; IMD1; BPK; B-cell progenitor kinase; agammaglobulinaemia tyrosine kinase; dominant- ......
Chromosomal LocationXq21.33-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BTK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBTK
NameBruton agammaglobulinemia tyrosine kinase
Aliases ATK; XLA; PSCTK1; AGMX1; IMD1; BPK; B-cell progenitor kinase; agammaglobulinaemia tyrosine kinase; dominant- ......
Chromosomal LocationXq21.33-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BTK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BTK.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBTK
NameBruton agammaglobulinemia tyrosine kinase
Aliases ATK; XLA; PSCTK1; AGMX1; IMD1; BPK; B-cell progenitor kinase; agammaglobulinaemia tyrosine kinase; dominant- ......
Chromosomal LocationXq21.33-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BTK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBTK
NameBruton agammaglobulinemia tyrosine kinase
Aliases ATK; XLA; PSCTK1; AGMX1; IMD1; BPK; B-cell progenitor kinase; agammaglobulinaemia tyrosine kinase; dominant- ......
Chromosomal LocationXq21.33-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BTK expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBTK
NameBruton agammaglobulinemia tyrosine kinase
Aliases ATK; XLA; PSCTK1; AGMX1; IMD1; BPK; B-cell progenitor kinase; agammaglobulinaemia tyrosine kinase; dominant- ......
Chromosomal LocationXq21.33-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BTK and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBTK
NameBruton agammaglobulinemia tyrosine kinase
Aliases ATK; XLA; PSCTK1; AGMX1; IMD1; BPK; B-cell progenitor kinase; agammaglobulinaemia tyrosine kinase; dominant- ......
Chromosomal LocationXq21.33-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BTK collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting BTK.
ID Name Drug Type Targets #Targets
DB01254DasatinibSmall MoleculeABL1, ABL2, BCR, BTK, CSK, EPHA2, EPHA5, EPHB4, FGR, FRK, FYN, HSP ......22
DB01863Inositol 1,3,4,5-TetrakisphosphateSmall MoleculeAKT1, BTK, CYTH2, CYTH3, DAPP1, ITPKA, PDPK1, PLEKHA48
DB05204XL418Small MoleculeBTK1
DB09053IbrutinibSmall MoleculeBTK1
DB11703AcalabrutinibSmall MoleculeBTK1